How FDA Classifies Medical Devices
FDA classifies devices into three regulatory classes based on the level of control necessary to assure the safety and effectiveness of the device. Class I devices carry the lowest risk, Class II devices are moderate risk, and Class III devices are high risk. The device classification decides the level of control FDA applies, and the pathway required for FDA clearance to market.
Every device type is assigned a three-letter product code in FDA’s Product Classification Database. The classification regulation, risk class, the FDA review panel that handles the review, and whether it is exempt from 510(k) is governed by the product code assigned to the device.
Read more about Medical Device Classification under US FDA →
Regulatory Pathways at a Glance
| Pathway | Used for | FDA review goal* (best case) | Typical fee (FY 2027, standard) |
|---|---|---|---|
| Self-registration & listing only | Most Class I and some Class II devices | Not applicable | Annual establishment fee only |
| Premarket Notification 510(k) | Most Class II and some Class I devices with a predicate | 90 days | 510(k) fee + Annual establishment fee |
| De Novo | Novel Class II devices with no predicate | Within 150 days | De Novo fee + Annual establishment fee |
| Premarket Approval (PMA) | Class III, high-risk devices | Within 180 days | PMA fee + Annual establishment fee |
*FDA "review days" pause while FDA waits for your answers to questions, so calendar time is longer.
Read more about Medical Device User Fees →
Self-Registration and Listing (510(k)-Exempt Devices)
Almost all of Class I devices, and a some of Class II devices, are exempt from 510(k) (see list here). For such devices, there is no premarket submission. They may also be exempt from the current Device Good Manufacturing Practices (GMP), requirements under the Quality Management System Regulation (QMSR). Devices exempt from the 510(k) requirements include:
- Preamendments devices
- Class I devices that are not intended for a use of substantial importance in preventing impairment of health and do not present a potential unreasonable risk of illness or injury, or that are specifically exempted by the FDA
- Class II devices that are specifically exempted by the FDA.
In such cases, you need to only register your establishment and list the device. Exempt does not mean unregulated, though. General controls still apply, including labeling, medical device reporting and the QMSR requirements for your device type.
The steps are short:
- Confirm your product code and make sure the device really is exempt, limitations included.
- Pay the annual establishment registration fee.
- Register the establishment and list each exempt device under its product code.
- Note: Foreign establishments must also name a U.S. Agent.
- Get your labeling right and, where required, submit UDI data to GUDID. Maintain general controls like records, complaint files etc.
- Renew registration every year between October 1 and December 31 to keep your listing current.
Premarket Notification 510(k)
Most moderate-risk (Class II) medical devices entering the U.S. market require a 510(k) premarket notification, to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device (also called predicate device). Submitters must compare their device to one or more similar legally marketed devices and make and support their substantial equivalence claims. This process requires a well-substantiated comparison of intended use, technological characteristics, and performance data. Errors or gaps in the substantial equivalence claims are among the leading causes of FDA delays and Requests for Additional Information (AI letters).
You cannot market a device until the FDA issues an order declaring it substantially equivalent (SE). Once SE status is granted, the device can be sold in the U.S. This determination is usually made within about 90 days, based on the information you submit.
De Novo Classification
De Novo is the regulatory pathway for new devices of low to moderate risk that have no suitable predicate, so they cannot go through a 510(k). This provides a marketing pathway when general controls, or general plus special controls, are enough to give reasonable assurance of safety and effectiveness of a device. Devices classified into Class I or Class II through a De Novo classification request may be marketed and used as predicates for future premarket notification submissions, when applicable.
There are two ways to submit a De Novo request for FDA to make a risk-based classification into Class I or II:
- Option 1: After receiving a ‘Not Substantially Equivalent’ (NSE) determination in response to a 510(k). This happens when FDA finds no suitable predicate, the device has a new intended use, or its technology raises new safety and effectiveness questions.
- Option 2: Directly, if the requester determines there is no legally marketed device to compare against. In this case, you can submit a De Novo without first filing a 510(k) and receiving an NSE
When FDA receives a De Novo request, it first checks that the submission is complete. In eSTAR this is largely automated through a virus scan and technical screening within 15 calendar days, and it starts only once the user fee is paid. If the eSTAR is incomplete, FDA emails the gaps and places the request on hold. If no replacement arrives within 180 days, the request is considered withdrawn. Once it passes screening, the review clock counts from the day FDA received it.
FDA then begins the substantive review. It checks whether a legally marketed device of the same type already exists, which confirms the device is eligible for De Novo. Where possible, FDA resolves deficiencies through interactive review, without a formal letter. The FDA’s goal is to provide De Novo decision within 150 review days.
Premarket Approval (PMA)
PMA is the US FDA's most rigorous review to evaluate the safety and effectiveness of Class III devices. These are high-risk devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. These may include items such as stent, pacemakers, cochlear implants, balloon catheter etc. You have to give FDA valid scientific evidence, usually including clinical data, that the device is safe and effective for its intended use.
The PMA application follows a four-step review process:
- Step 1Administrative and limited scientific review — FDA staff check completeness through acceptance and filing reviews.
- Step 2Substantive review — In-depth scientific, regulatory, and Quality System evaluation by FDA personnel.
- Step 3Advisory committee review — A panel provides recommendations based on the application.
- Step 4Final FDA decision — Deliberations, documentation, and formal notification of the outcome
The FDA requires a PMA application to be well-structured, consistent, and supported by sufficient scientific data. If the application is incomplete or inaccurate, approval may be delayed or denied. Each PMA must include the following technical sections:
- Non-clinical laboratory studies: Results from microbiological, toxicological, immunological, biocompatibility, stress, wear, shelf-life, and other laboratory or animal tests, conducted under Good Laboratory Practice (GLP) standards.
- Clinical investigations: Data from human clinical trials, including study design, patient information, device safety and effectiveness, adverse effects, and failures.
Proposed marketing materials such as instructions for installation and use, advertising, or other materials must also be included in the application.
FDA also inspects your manufacturing and quality system. Approval often comes with conditions, such as post-approval studies, and you will have to file annual reports and supplements for changes afterward. FDA's goal is a decision within 180 FDA days, but with clinical trials it generally takes longer.
Establishment Registration
Registration and listing aren't a one-time task. FDA expects them when you start, every year, and whenever something changes.
Initial registration: Submit your registration and listing information within 30 days of starting an activity or putting a device into commercial distribution. If your device needs premarket submission, you have to wait until FDA has cleared or approved it before you register your establishment and list the device.
Annual registration: Every year between October 1 and December 31, you must submit your registration information, even if nothing has changed. Review your listing information in the same window and submit any updates. Registrations follow FDA's fiscal year (October 1 to September 30), but FDA treats a registration as active through the end of the calendar year.
Updates during the year: You don't have to wait for the annual window. Owners and operators can log in to FURLS at any time to update their records, for example when you:
- introduce another device into commercial distribution,
- change a listed device, such as where it is manufactured, or
- remove a listed device from distribution or resume distributing it.
For more details see FDA When to register and List page
Q-Submission Program
The Q-Submission (Q-Sub) program is FDA's voluntary way to request feedback and meetings on a device submission. The best-known type is the Pre-Submission (Pre-Sub). It lets you put specific questions to FDA before you file, on things like testing protocols, applicable standards, substantial equivalence and regulatory strategy. FDA can answer in writing only, or in writing followed by a meeting.
A Pre-Sub is not required before a 510(k). However, it works best when it comes first. Manufacturers who test first and ask later sometimes discover they ran the wrong study.
You find gaps while they are still cheap to fix. The same gaps found during formal review become deficiencies and Additional Information requests.
You can confirm your approach before spending on bench, animal or clinical studies.
You get FDA's position on your specific questions, which can strengthen your later submission and help it move more smoothly.
FDA's feedback is its best advice based on what you submitted, and it does not guarantee a favorable decision later. Still, FDA states that feedback generally won't change if your submission is consistent with the Pre-Sub, unless important new issues come up.
What you bring matters most. Narrow, well-supported questions get usable answers. Broad or vague ones can leave you with ten weeks gone and little to show for it. Need any help? Reach out to us today.
Need for US Agent
Any foreign manufacturer seeking to market a medical device in the United States is required by the FDA to designate a U.S. Agent, a U.S.-based point of contact responsible for communicating with the FDA on the manufacturer's behalf. The U.S. Agent assists with facility registration, receives correspondence during reviews and inspections, and helps relay urgent communications, including recalls or compliance notices.
Without a properly designated U.S. Agent, a foreign establishment cannot register with the FDA, making this a foundational, non-negotiable requirement for market entry. We help manufacturers understand this obligation, ensure proper designation, and maintain accurate, up-to-date FDA registration records.
Don't have a U.S. Agent yet? We can put you in touch with a vetted, reliable partner to take on this role — so you have a dependable point of contact with the FDA from day one.
FDA Quality Management System Regulation
The FDA's Quality Management System Regulation (QMSR), which harmonizes the Quality System Regulation (21 CFR Part 820) with ISO 13485:2016, represents a significant shift in how device manufacturers must structure and demonstrate their quality systems. Transitioning to or building a QMS aligned with this updated framework requires a clear understanding of where FDA-specific requirements still diverge from ISO 13485, even as the two are harmonized.
The QMSR took effect on February 2, 2026, and FDA now inspects against ISO 13485:2016 as incorporated by reference. If you already hold ISO 13485 or MDSAP certification, you are ahead. But the QMSR still carries FDA-specific provisions that a certificate alone will not prove you meet. We map your current system against it, close the gaps, and prepare your team for inspector questions. For the audit side, see our MDSAP guide.
We provide:
- Gap analysis between your current QMS and QMSR requirements
- Guidance on aligning existing ISO 13485 systems with FDA-specific expectations
- Documentation and procedural updates to support compliance
- Ongoing consultation to prepare for FDA inspections under the new regulation
Our aim is to help you transition smoothly, minimizing disruption while ensuring your quality system remains inspection-ready.
Read more about FDA Quality Management System Regulation (QMSR) →